© 2020 MJH Life Sciences and HCPLive. All rights reserved.
July 21, 2020
Upadacitinib 15 mg and 30 mg outperformed placebo in Measure Up 2, the second part of a phase 3 study on the monotherapy.
July 20, 2020
Despite negative trial resutls, the data support the posibility of tapering off NSAIDs and the plausibility of self-management approaches like CBT.
July 01, 2020
The statement contains positions and oppositions for telemedicine, along with highlights barriers and opportunities for patients and rheumatology professionals.
June 16, 2020
Dr. Richard Furie explains the link between systemic lupus erthematosus and COVID-19.
June 09, 2020
The drug is well-tolerated in methotrexate inadequate response patients with rheumatoid arthritis.
Patients who cannot tolerate cDMARDs may experience additional value from tocilizumab compared to adalimumab.
June 07, 2020
Dr. Philip Mease discusses some of the treatments currently being tested for effectiveness against COVID-19.
Rheumatoid arthritis patients with probably major depressive disorder or generalized anxiety disorder were more likely to suffer from worse fatigue and pain.
A team investigated data from trials of tofacitinib, adalimumab, and placebo.
June 06, 2020
The safety profile of upadacitinib is consistent with phase 3 rheumatoid arthritis studies.